Interview with Jaime A. Ballester, CEO of Pratia Spain

Earlier this year Pratia and Ribera Salud Foundation formed a partnership to improve Patient access to innovative therapies in three of the Ribera Group hospitals.  

We sat down with Jaime A. Ballester, CEO of Pratia Spain, to talk about his perspective on this unique collaboration. 

Pratia: Can you elaborate on the goal of the Pratia-Ribera collaboration and its significance for clinical research in Spain? 

Jaime A. Ballester: The goal is to enhance Pratia’s clinical research capabilities by partnering with Ribera Salud’s extensive and established network of hospitals. This collaboration aims to accelerate the development of new treatments and ensure that more Spanish Patients have timely access to the latest therapeutic advancements. By combining our expertise in clinical trials with Ribera’s robust healthcare infrastructure, we can streamline research processes and improve Patient outcomes across Spain. 

Pratia: What unique synergies does this cooperation bring? 

Jaime A. Ballester: Ribera provides access to experienced healthcare professionals and a wide Patient population. Pratia’s SMO experience and expertise boosts the operational efficiency of clinical trials, enabling access to the best clinical trials technologies and ensuring adherence to the highest standards of quality and safety. By leveraging Ribera’s established network and Pratia’s specialized knowledge, we can conduct more effective and impactful research, which will allow us to carry out jointly a greater number of first-line clinical trials with high-level management, from Phase I to Phase IV

Pratia: How will we collaborate with healthcare professionals and researchers? 

Jaime A. Ballester: To add to the aforementioned synergies, our collaboration results in several aspects: 

• Promotion of state-of-the-art research approaches among research teams 

• Possibility of continuous education and training via Pratia’s initiatives such as: Site Management Alignment Program or Site Management Excellence Academy. 

• Knowledge dissemination: Ensuring highest quality of knowledge and experience sharing among the teams for overall best results. 

Pratia: What upcoming initiatives can we expect from this alliance? 

Jaime A. Ballester: Future initiatives include expanding the network of centers and researchers, promoting international collaboration, and improving further the Patient experience. 

With these insights, it’s clear that the Pratia-Ribera Salud partnership is poised to make a significant impact on clinical research in Spain, enhancing patient care and advancing medical knowledge. The combination of resources, expertise, and a shared commitment to innovation positions this alliance as a leading force in the healthcare sector. We look forward to seeing the positive outcomes of this collaboration and the upcoming initiatives that will further drive progress in Clinical Trials.